Regimen Reference Order – GYNE – PACLitaxel (weekly for 3 doses)

ARIA: GYNE - [PACL (80 mg/m2 x 3/4 wks)]

Planned Course: Once a week for 3 weeks, then 1 week off until disease progression or unacceptable toxicity (1 cycle= 28 days) Indication for Use: Ovarian Carcinoma Recurrent

CVAD: At Provider's Discretion

Proceed with treatment if:

Cycle 1, Day 1

• ANC equal to or greater than 1.5×10^9 /L AND Platelets equal to or greater than 100×10^9 /L Cycle 1, Day 8 and Onwards

- ANC equal to or greater than 1.2×10^9 /L AND Platelets equal to or greater than 75 x 10^9 /L
 - Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
		Not Applicable		

Establish primary solution 500 mL of normal saline				
Drug	Dose	CCMB Administration Guideline		
Days 1, 8 and 15				
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel		
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel *Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion		
Wait 1 hour after con	npletion of IV pre-m	edication(s) before starting PACLitaxel		
PACLitaxel	80 mg/m ²	 IV in normal saline 250 mL over 1 hour, following the administration rates below: Administer at 100 mL/hour for 15 minutes, then Administer remaining volume over 45 minutes Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter 		
		*Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'



REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine, urea, electrolytes and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Days 8 and 15

- CBC as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

• PACLitaxel may cause progressive, irreversible neuropathy

